Connect with us

Technology

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Published

on

CAMBRIDGE, Mass., Aug. 30, 2024 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense” or the “Company”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”). The letter notifies the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company’s ordinary shares listed on the Nasdaq was below USD $1.00 for 30 consecutive trading days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of USD $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.

The Notice has no immediate effect on the Company’s Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the Company’s ordinary shares will continue to trade on the Nasdaq under the symbol “NRSN”.

In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until February 24, 2025, to regain compliance with the minimum bid price. If at any time before February 24, 2025 the bid price of the Company’s ordinary shares closes at or above USD $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement.

In the event the Company does not regain compliance by February 24, 2025, the Company may be eligible for an additional 180 days to regain compliance if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case, the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period.

The Company will continue to monitor the closing bid price of its ordinary shares on the Nasdaq between now and February 24, 2025 and seek to cure the deficiency within the prescribed compliance period.  The Company’s business operations are not affected by the notification letter.

If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq’s staff will notify the Company that its ordinary shares are subject to delisting.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. For example, the Company is using forward-looking statements when it discusses regaining compliance with Nasdaq’s continued listing requirements, and timing and effect thereof. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements relating to the consummation of the offering described above, the expected proceeds from the offering, the intended use of proceeds and the timing of the closing of the offering. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include unexpected R&D costs or operating expenses, a delay in the reporting of additional results from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2024 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-announces-receipt-of-nasdaq-minimum-bid-price-notification-302234276.html

SOURCE NeuroSense

Continue Reading

Technology

Trive Capital Announces Sale of EarthLink

Published

on

By

DALLAS, Oct. 20, 2026 /PRNewswire/ — Trive Capital (“Trive”) is pleased to announce that it has closed on the sale of EarthLink, LLC (“EarthLink” or the “Company”) to a family office consortium consisting of WaveDivision Capital (“Wave”), The Pritzker Organization (“TPO”) and Stephens Capital Partners (“SCP”), in partnership with EarthLink’s management team. Headquartered in Atlanta, Georgia, EarthLink is one of the largest internet service providers in the United States, serving over 500,000 internet and managed services customers nationwide. Through partnerships with several of the nation’s largest fiber and 5G providers, EarthLink has built an asset-light, nationwide network that can offer fiber internet service to more than 68 million homes.

Since Trive’s investment in EarthLink in 2018 as part of a corporate carveout, the Company has transformed from a legacy DSL and email business in precipitous decline to an asset-light connectivity platform serving over 500,000 consumers and small businesses nationwide. The Company has grown and will continue to grow based on its expanded fiber and 5G internet solutions and commitment to customer service for consumers and small businesses.

Shravan Thadani, Partner at Trive, stated, “EarthLink has been a true partnership between management and Trive in every sense of the word. The team built a differentiated, asset-light platform that gives consumers and small businesses real choice in how they get connected, and did so while standing up every function of the platform outside of its former, public parent. We are proud to have been a part of such an iconic brand’s journey and will continue to support Wave, TPO and SCP as they work with management to accelerate growth in the coming years.”

“During our partnership with Trive, we have taken one of the most trusted brands in the internet space and turned it into a trusted option for consumers and small businesses nationwide,” commented Glenn Goad, Chief Executive Officer of EarthLink. “As internet access has become one of the most important utilities in a consumer’s life, EarthLink has a renewed focus on making it easier for our customers to access the best internet options at affordable prices. Trive was critically important through and after the carve-out, and we are excited to partner with Wave, TPO and SCP to continue to grow EarthLink alongside our trusted fiber and 5G partners. Our collective goal remains the same: to provide the right technology at the right price, supported by a world-class customer experience.”

About EarthLink

EarthLink is an internet service provider offering fiber and 5G internet solutions for homes and businesses nationwide. With a focus on dependable connectivity, flexible plans, and customer-focused service, EarthLink provides broadband options designed to meet the needs of modern households and businesses. EarthLink is headquartered in Atlanta, Georgia and serves over 500,000 customers. To learn more, visit earthlink.net.

About Trive Capital

Trive Capital is a Dallas, Texas based private equity firm with more than $8 billion of regulatory assets under management. Trive focuses on investing equity and debt in what it sees as strategically viable middle-market companies with the potential for transformational upside through operational improvement.

The Trive team is comprised of seasoned investment professionals who have been involved in over 250 middle-market transactions representing in excess of $10 billion in revenue across Trive’s targeted industry sectors and situations.

View original content to download multimedia:https://www.prnewswire.com/news-releases/trive-capital-announces-sale-of-earthlink-302914673.html

SOURCE Trive Capital

Continue Reading

Technology

Rondo Energy and Rio Tinto Advance Australia’s Largest Thermal Energy Storage Project

Published

on

By

GLADSTONE, Australia, Oct. 20, 2026 /PRNewswire/ — Rondo Energy and Rio Tinto have started front-end engineering and design on the project for a 360 MWh storage / 30 MW discharge Rondo Heat Battery, supported by a grant from the Australian Renewable Energy Agency (ARENA).

ARENA’s funding for the project will be provided in stages, with an initial $3.6 million to complete front-end engineering and design work. Following successful completion of that study, ARENA will provide up to $38 million for deployment. ARENA has also approved up to $33.3 million in conditional contingency support, which would only be made available in defined circumstances to manage specific project risks, including cost overruns and electricity costs. 

If progressed, the project would be delivered at Rio Tinto’s Yarwun alumina refinery near Gladstone, Queensland and would be one of the first large-scale demonstrations of thermal energy storage for industrial process heat globally, and a world-first for the alumina industry.

Rondo Heat Batteries use abundant, low-cost midday electricity to charge, storing energy as high-temperature heat in refractory brick, and supplying energy as 24/7 continuous process heat to industry. Typically, the heat is delivered as steam, directly into an industrial facility’s steam network. Australia regularly has 4-6 hours of surplus solar-generated renewable electricity in the middle of the day, but industrial facilities need heat 24 hours a day, not just when the sun is shining. By charging when electricity is cheap and abundant and discharging continuously, Rondo Heat Batteries turn short periods of low-cost electricity into 24/7 delivery of low-cost steam. 

For energy-intensive industries such as alumina refining, Rondo Heat Batteries create a pathway to electrification that addresses both emissions and energy costs. Because the heat battery slots into the existing steam network, the facility’s processes run exactly as before — the only thing that changes is the energy for that heat: no longer from fossil fuels, but sourced from low cost electricity instead. The Yarwun study will assess the technical and economic viability of integrating the technology into refinery operations.

“This project shows how Australia’s abundant energy can become a competitive advantage for industry,” said Dr. Kira Rundel, Rondo’s Head of Australia. “Heat batteries allow manufacturers to use low-cost electricity to produce the reliable, round-the-clock heat their operations need. Australia’s largest heat battery will show how factories can cut emissions without increasing energy costs, helping Australian industry to increase global competitiveness and supporting local manufacturing jobs.”

Rio Tinto Pacific Operations Managing Director Armando Torres said: “Reducing emissions from alumina refining is complex, particularly when it comes to generating the high-pressure steam needed for our operations.

“This study will help us determine whether thermal energy storage can provide a technically and economically viable alternative to fossil fuels for part of Yarwun’s steam requirements.

“The best way to tackle challenges of this scale is through collaboration between industry, government, and technology partners. We welcome ARENA and Rondo’s support as we assess technologies that could help reduce our Scope 1 emissions while maintaining reliable operations at Yarwun.”

About Rondo Energy

Rondo Energy delivers firm heat and power, including combined heat and power (CHP), to heavy industry and provides power solutions and long duration storage to data centers. For industrial heat applications, Rondo Heat Batteries convert 4-6 hours of low-cost electricity into continuous 24-hour, high-temperature heat, delivered as steam or hot air up to 1,000°C. The heat delivered integrates directly with existing industrial equipment and processes, eliminating on-site emissions and running on lower cost energy. Rondo heat storage can integrate with steam turbines to deliver combined heat and power (CHP) for industry, and long duration power-to-power solutions for large energy consumers such as data centers. Built on proven refractory brick as the thermal storage medium, Rondo’s platform is engineered for multi-decade operation in the most demanding industrial environments.

Rondo Heat Batteries have been delivering firm heat and power at scale since 2023, with operational facilities serving customers in fuels and cement (including steam driving turbines for electricity) in the United States and in Asia. The next unit will come online shortly – a 100 MWh Rondo Heat Battery under construction in Europe for a chemical plant. Rondo is a global company based in California, with teams across North America, Europe, the Middle East, and Australia. Providing heat and power solutions to the alumina industry is an area of focus for the company due to the strong fit of Rondo’s technology with the heat and power needs of the alumina industry.

View original content to download multimedia:https://www.prnewswire.com/news-releases/rondo-energy-and-rio-tinto-advance-australias-largest-thermal-energy-storage-project-302914664.html

SOURCE Rondo Energy

Continue Reading

Technology

14 Organizations Earn CHIME’s Highest Digital Health Most Wired Designation for 2026

Published

on

By

ANN ARBOR, Mich., Oct. 20, 2026 /PRNewswire/ — The College of Healthcare Information Management Executives (CHIME), the leading professional organization for digital health leaders, today announced 14 organizations have achieved Level 10 in the 2026 CHIME Digital Health Most Wired (DHMW) survey. Powered by Digital Health Analytics (DHA), the survey is CHIME’s global assessment of digital health excellence, with Level 10 as its highest designation.

Representing health systems across the U.S., this year’s Level 10 organizations demonstrated exceptional performance across the enterprise digital ecosystem, leveraging technologies, data, infrastructure, and strategic practices shaping modern care delivery. The prestigious designation recognizes organizations that have moved beyond technology implementation to integrate digital investment across clinical and operational environments, producing measurable value for their health systems, patients, and providers.

The 2026 DHMW survey maintains a rigorous scoring methodology designed to account for differences in organizational size, complexity, risk, and resources, creating an equitable measure of performance across diverse healthcare environments. The model evaluates organizations across 10 distinct segments, measuring both the foundational elements required for digital maturity and the advanced practices that demonstrate broader adoption, integration, and value.

“Healthcare is experiencing extraordinary technological acceleration, driven in large part by the rapid adoption of AI and increasingly sophisticated digital capabilities,” said Russ Branzell, President and CEO of CHIME. “As that pace intensifies, the Digital Health Most Wired Survey continues to provide a rigorous benchmark for evaluating whether technology is translating into meaningful progress. It gives leaders a data-driven view of performance, critical gaps, and opportunities for high-impact investment while setting an industry standard of excellence for responsible technology adoption. The Level 10 organizations recognized this year exemplify the leadership and innovation required to turn digital investment into measurable improvements in care delivery.”

The 2026 Digital Health Most Wired survey includes data from more than 45,000 facilities worldwide, offering a global view of technology adoption, investment and performance across healthcare organizations and the evolving role of digital health in care delivery, operations and the patient and provider experience.

Each participating organization received a customized benchmarking report through the Digital Health Analytics (DHA) portal, offering detailed insights into performance metrics across 10 key segments:

InfrastructureSecurityAdministrationSupply chainAnalytics and data managementInteroperabilityPopulation healthPatient engagementInnovationClinical quality and safety

Fourteen healthcare organizations achieved Level 10 distinction, the highest designation awarded through the 2026 CHIME Digital Health Most Wired survey. The recipients are Baptist Health System (Jacksonville, Florida); Bon Secours Mercy Health (Ohio); MetroHealth Medical Center (Ohio); MultiCare Health System (Washington); Northeast Georgia Health System (Georgia); NYU Langone Health (New York); Parkview Health (Indiana); Roper St. Francis Healthcare Services, Inc. (South Carolina); Stanford Health Care (California); UCHealth (Colorado); UNC Health (North Carolina); University Health (Texas); University of Utah Health (Utah); and UPMC (Pennsylvania).

Collectively, the 2026 Level 10 designees reflect a healthcare environment in which digital performance increasingly depends on the alignment of technology strategy, data, infrastructure, and organizational priorities with strong leadership and a sustained commitment to innovation. Their results demonstrate how leading health systems are converting digital investment into measurable gains across clinical and operational environments while establishing the foundations required to responsibly adopt emerging technologies at scale.

CHIME will formally recognize these distinguished Level 10 honorees on November 12, 2026, during the CHIME26 Fall Forum in Denver, CO, which runs from November 11-14.

For additional details on the 2026 Digital Health Most Wired survey and the complete list of all Level 7-10 award recipients, visit dhanalytics.org.

About CHIME 
The College of Healthcare Information Management Executives (CHIME) is the leading professional organization for digital health executives and leaders. CHIME provides a trusted, collaborative environment where members and partners connect, share best practices, advance professional development, and advocate for the effective use of information and technology to improve health and care in the communities they serve. For more information, please visit chimecentral.org.

About Digital Health Analytics (DHA)
Digital Health Analytics provides healthcare organizations, technology companies, and academic researchers with the data, benchmarking, and market intelligence they need to lead digital transformation — 365 days a year. Powered by the College of Healthcare Information Management Executives (CHIME), DHA helps provider organizations supercharge their digital health transformation capabilities. For more information about DHA, visit dhanalytics.org.

For media inquiries, please contact:

Calli Dretke
Executive Vice President & Chief Digital and Marketing Officer
CHIME
734.665.0000
cdretke@chimecentral.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/14-organizations-earn-chimes-highest-digital-health-most-wired-designation-for-2026-302914691.html

SOURCE College of Healthcare Information Management Executives (CHIME)

Continue Reading

Trending